3.82 USD
↘ 0.08 (2.15%)PRE MARKET (AS OF 07:14 AM EST)
Prime Medicine, Inc. Common Stock
PRMENASDAQ • USD
Market: OPEN
Prime Medicine, Inc. Common Stock (PRME) trades at $3.82 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Nov 10, 2026.
Open?$3.76
High?$3.90
Low?$3.63
Prev. Close?$3.90
Volume?234.5K
Avg. Volume?5.5M
VWAP?$3.76
Rel. Volume?0.04x
Bid / Ask
Bid?$3.31 × 100
Ask?$4.63 × 100
Spread?$1.32
Midpoint?$3.97
Valuation & Ratios
Market Cap?707.4M
Shares Out?181.4M
Float?95.7M
Float %?52.7%
P/E Ratio?N/A
P/B Ratio?17.77
EPS?-$1.04
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Themes
Employees
146
Market Cap
707.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2022-10-20
Address
60 FIRST ST.
CAMBRIDGE, MA 02141
Phone: 617-465-0013
CAMBRIDGE, MA 02141
Phone: 617-465-0013
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?0
Momentum?75
Short Sent.?48
Piotroski F-Score?1/9Weak
Altman Z-Score?-5.84Distress
Confidence?53%Low
Short InterestSqueeze Risk
Short % of Float?30.47%Squeeze Risk
Short Interest?29.1M
Days to Cover?4.8
Free Float95.7M
Avg Daily Volume6.1M
Settlement Date2026-10-30
Financial Health
Current Ratio?1.95Adequate
Quick Ratio?1.95Adequate
Cash Ratio?0.95Adequate
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 2 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?17.77HIGH▾
Peers33
S&P9
P/S?173.67HIGH▾
Peers67
S&P3
P/FCF?N/A▾
EV/EBITDA?-3.5CHEAP▾
S&P97
EV/Sales?162.02HIGH▾
Peers67
S&P3
Returns & Efficiency
ROE?-472.0%WEAK▾
S&P3
ROA?-75.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-156848000
Enterprise Value?$659.9M
Fundamentals ratios updated end of day